As of December 15, 2025, Scopus Biopharma Inc (SCPS) reports a ROE (Return on Equity) of 176.86%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Scopus Biopharma Inc's ROE (Return on Equity)
Over recent years, Scopus Biopharma Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-12-31 | 176.86% |
| 2021-12-31 | -670.91% |
| 2020-12-31 | 593.44% |
| 2019-12-31 | 3362.50% |
| 2018-12-31 | 6900.00% |
This slight downward trend highlights how Scopus Biopharma Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Scopus Biopharma Inc's ROE (Return on Equity) to Peers
To better understand Scopus Biopharma Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Scopus Biopharma Inc (SCPS) | 176.86% |
| Palatin Technologies Inc (PTN) | 26669.16% |
| Marizyme Inc (MRZM) | 1402.10% |
| Evaxion A/S (EVAX) | 639.65% |
| TRACON Pharmaceuticals Inc (TCON) | 443.51% |
| Brainstorm Cell Therapeutics Inc (BCLI) | 149.70% |
Compared to its competitors, Scopus Biopharma Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.